Working with the NHS
At Bristol Myers Squibb, we recognise the significant challenges facing the NHS. The public rightly want fast access to high quality care at a time and place that is convenient to them.
At the same time, the global recession means budgets are increasingly constrained. The challenge for the NHS, therefore, is to meet these public expectations with tighter resources.
We believe our portfolio of existing and pipeline medicines can be part of the solution to these challenges. These new medicines will offer opportunities for the NHS to provide patients with better outcomes and better quality of life. Yet we also recognise that new treatments will present challenges to the NHS.
New medicines often increase the upfront cost of healthcare. They may also require staff training, new capacity or changes to patient pathways. At a time when resources are stretched it is ever more important that the NHS gets the most out of the new medicines it invests in, in terms of both clinical outcomes and patient experience.
In recognition of this, our approach at Bristol Myers Squibb is to work in partnership with the NHS to make sure it gets maximum value from our medicines.
Our teams are becoming more flexible when it comes to meeting customer needs rather than trying to apply a one-size-fits-all solution. In fact, we are now regularly having conversations with payers about providing a whole service and not just medicines.
Partnerships that bring value to the NHS
In order to meet its chosen strategy, every partnership entered into by Bristol Myers Squibb with the NHS must be underpinned by four key undertakings:
- Bristol Myers Squibb endeavours to continually develop medicines to meet true unmet medical need across a range of disease areas
- We are committed to enhancing clinical excellence through clinical research activities
- We will provide robust evidence on our medicines to support NHS decision makers
- Bristol Myers Squibb is striving to improve its service delivery so that its medicines reach the right patients at the right time.
| NHS Trust Name | Collaborative Working Project | Documents |
|---|---|---|
| UK Oncology Nursing Service (UKONS) | Development of a National E-Learning Training programme for NHS Staff undertaking UK Oncology Nursing Service (UKONS) guided 24 Hour Telephone Triage of Oncology/Haematology Patients | Outcomes Report |
| Macmillan Cancer Support | Demonstrating the Value of Prehabilitation through Service and Workforce Efficiencies | Outcomes Report |
| Macmillan Cancer Support | Forecasting for innovation: A workforce planning tool | Outcomes Report |
| Guy’s and St Thomas’ Hospitals NHS Foundation Trust (GSTT part of King’s Health Partners (KHP) | Improving care for patients with Hypertrophic Cardiomyopathy (HCM) by embedding digital solutions and service development | Outcomes Report |
| Guys’ and St Thomas’ NHS Trust and University Hospitals Birmingham NHS Foundation Trust | Implementing guideline-based pathway redesign for Hypertrophic Cardiomyopathy patients | Summary of Collaborative Working Agreement |
| Liverpool Heart and Chest Hospital NHS Foundation Trust | Implementation of a pilot community based Inherited Cardiac Conditions (ICC) service | Summary of Collaborative Working Agreement |
| Manchester University NHS Foundation Trust | Standardised registry of hypertrophic cardiomyopathy (HCM) patients in the UK as a pilot across several sites in Northern England and Scotland | Summary of Collaborative Working Agreement |
| Barts Health NHS Trust | Implementation of ESC guidelines for the management of cardiomyopathies through the sustainable expansion of a nurse-led LVOT obstruction clinic | Summary of Collaborative Working Agreement |
| Manchester University NHS Foundation Trust | Mobile assessment clinic to enhance equity of service delivery to patients with inherited cardiac conditions | Summary of Collaborative Working Agreement |
| NHS Lothian | Establishing a new ICC clinic in Scotland | Summary of Collaborative Working Agreement |
NO-GB-2600077
Date of preparation: August 2026